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Abstract
Background: Acquired antibodies are important in human immunity to malaria, but key targets remain largely unknown.
Plasmodium falciparum reticulocyte-binding-homologue-4 (PfRh4) is important for invasion of human erythrocytes and may
therefore be a target of protective immunity.
Methods: IgG and IgG subclass-specific responses against different regions of PfRh4 were determined in a longitudinal
cohort of 206 children in Papua New Guinea (PNG). Human PfRh4 antibodies were tested for functional invasion-inhibitory
activity, and expression of PfRh4 by P. falciparum isolates and sequence polymorphisms were determined.
Results: Antibodies to PfRh4 were acquired by children exposed to P. falciparum malaria, were predominantly comprised of
IgG1 and IgG3 subclasses, and were associated with increasing age and active parasitemia. High levels of antibodies,
particularly IgG3, were strongly predictive of protection against clinical malaria and high-density parasitemia. Human
affinity-purified antibodies to the binding region of PfRh4 effectively inhibited erythrocyte invasion by P. falciparum
merozoites and antibody levels in protected children were at functionally-active concentrations. Although expression of
PfRh4 can vary, PfRh4 protein was expressed by most isolates derived from the cohort and showed limited sequence
polymorphism.
Conclusions: Evidence suggests that PfRh4 is a target of antibodies that contribute to protective immunity to malaria by
inhibiting erythrocyte invasion and preventing high density parasitemia. These findings advance our understanding of the
targets and mechanisms of human immunity and evaluating the potential of PfRh4 as a component of candidate malaria
vaccines.
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Introduction
Malaria due to Plasmodium falciparum remains a major global
health burden and a leading cause of death worldwide among
children under five [1,2]. Increasing drug resistance, including
emerging resistance to the artemisinin drugs, and the declining
efficacy of vector control interventions in some populations make
the development of effective malaria vaccines an urgent priority.
During blood-stage infection, P. falciparum merozoites invade
erythrocytes, mediated by the release of invasion ligands from
apical organelles that interact with receptors on the erythrocyte
surface [3,4]. The repertoire of invasion ligands includes two
major families, the P. falciparum reticulocyte-binding homologues
(PfRh), and erythrocyte binding antigens (EBAs) [3,4]. The ability
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of P. falciparum to vary the expression and/or use of EBA and PfRh
proteins enables the use of alternate invasion pathways [5,6],
facilitating immune evasion that enables P. falciparum to cause
repeated and chronic infections [7]. Invasion pathways can be
broadly classified into two main pathways, sialic acid (SA)-
dependent invasion and SA-independent invasion.
The PfRh ligands are located in the rhoptries of merozoites and
include PfRh1, PfRh2a, PfRh2b, PfRh4 and PfRh5 [3,6,8,9,10].
PfRh4 binds to complement receptor 1 and is essential for SA-
independent invasion [6,11,12,13], whereas the EBAs and PfRh1
are important for SA-dependent invasion [8,14,15,16,17,18].
Expression of PfRh4 varies among isolates, but knowledge on
the extent of variation and the frequency of expression of PfRh4
by isolates is limited. There are data on expression of the Pfrh4
gene by isolates from infected individuals in Africa [19,20], and
data on PfRh4 expression by a small number of laboratory-
adapted isolates [6,11,21]; however, there are presently no data on
expression of PfRh4 protein by clinical isolates, or data from
populations outside Africa.
Protective immunity to malaria eventually develops after
repeated exposure, and is thought to prevent disease by controlling
blood-stage parasitemia [22,23,24,25]. Despite an expanding
knowledge of the genomics and proteomics of P. falciparum, few
antigens have been studied as immune targets in humans [22,23]
and there is a paucity of data on functional immune responses to
specific antigens. These gaps have restricted our knowledge of
immunity and impeded progress towards developing effective
vaccines. Antibodies to erythrocyte invasion ligands may act by
directly inhibiting parasite replication, possibly also through
antibody dependent cellular inhibition, and opsonization of
merozoites for phagocytosis [7,22,26,27,28,29,30,31]. Very little
is known about immune responses to PfRh proteins. An initial
study in Kenya reported that antibodies to PfRh2 and PfRh4 were
acquired in an age-dependent manner, reflecting the acquisition of
immunity in the population, and antibodies to PfRh2 were
associated with protective immunity in a prospective study of
children [7,30]. In light of the important role of PfRh4 in invasion,
we have evaluated PfRh4 as a target of human immunity.
Materials and Methods
Protein Expression
Recombinant protein PfRh4.9 (amino acids [aa] 28–766;
Figure 1) contains the erythrocyte binding region of PfRh4, and
the expression, purification, and functional binding activity of the
protein has been previously reported [32]. In brief, it was
expressed as a (His)6 fusion protein, and subsequently purified
on a Ni-nitrilotriacetic acid column followed by a Superdex gel
filtration column. Recombinant proteins PfRh4.2 (amino acids aa
1277–1451), PfRh4.1 (aa 607–773) and PfRh4.4 (aa1445–1619)
were expressed as GST fusion proteins and purified on a
glutathione agarose column (Sigma-Aldrich, Sydney, Australia),
and then dialysed against PBS, as previously described [6]. The
PfRh4 sequence used was from the reference isolate 3D7.
ELISA
IgG and IgG subclass reactivity to recombinant proteins were
measured by ELISA using established methods [25,30,31]. Sera
were tested at 1/500. Samples were classified as antibody positive
if the OD.mean+3SD of reactivity observed with non-exposed
sera. Reactivity of antibodies among samples to GST was
negligible.
Study Population and Ethics Approval
Plasma samples were obtained from a prospective treatment re-
infection study of 206 children from Mugil, Madang Province,
Papua New Guinea (PNG) described in detail elsewhere [33];
median age was 9.3 years (range: 5–14). At enrolment the
prevalence of P. falciparum was 67.5% (n= 139) by PCR and 40.3%
(n= 83) by light microscopy (the geometric mean parasite density
was 361 parasites/ml (95% CI, 240–544). After enrolment, all
children received 7 days of artesunate orally. Children were
reviewed 2-weekly for 6 months for symptomatic illness and
parasitemia by PCR and microscopy, and by passive case
detection. A clinical episode of P.falciparum malaria was defined
as fever and P.falciparum parasitemia .5000/ml. During the follow-
up period, 80 children experienced clinical malaria, 196 had re-
infection by PCR, and 180 had re-infection detected by light
microscopy. Samples used were those taken at enrolment, prior to
artesunate treatment. Sera were also obtained from anonymous
Australian residents as controls. Ethical approval for this study was
obtained from the Medical Research Advisory Committee, PNG
and the Human Research Ethics Committees of the Walter and
Eliza Hall Institute and Alfred Hospital, Australia. Written
informed consent was obtained from subjects and their guardians.
Statistical Analysis
Statistical analysis was performed using STATA 9.2 (STATA-
Corp, College Station, Texas, USA). Differences in seroprevalence
and IgG levels between categorical variables were assessed using
chi-square tests or Kruskal Wallis tests, respectively. To determine
the association between antibody levels and subsequent episodes of
P. falciparum infection and symptomatic malaria, children were
stratified into three equal groups (tertiles) reflecting low (including
those who were classified as sero-negative), medium and high
responders according to OD values for each antigen; the risk of
malaria and parasitemia was compared between responder
groups, as used previously [30,31]. Although some children had
Figure 1. PfRh4 is a target of human antibodies. (a) Schematic
representation of the PfRh4 recombinant proteins used in this study,
relative to full length PfRh4. TM: transmembrane domain. Numbers
represent amino acids. (b) IgG reactivity to PfRh4 recombinant proteins
measured by ELISA. Results are shown as median OD and interquartile
ranges by age group (# or .9 years of age) or parasitemic status (PCR-
or PCR+) for PfRh4.2 (left panel) and PfRh4.9 (right panel).
doi:10.1371/journal.pone.0045253.g001
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multiple episodes of parasitemia or malaria, analysis included time
to first re-infection or first symptomatic episode only. All children
were treated with 7 days artesunate, orally, at enrolment to clear
existing parasitemia, and treatment efficacy was 91.4% (as
determined by PCR) [33]. Treatment failures (n = 12) were
differentiated from re-infection by genotyping of msp2, and were
excluded from the analysis. The Cox proportional hazards model
was used to calculate hazard ratios for risk of malaria between
antibody responder groups. For antibody variables that showed
non-proportional hazards, an interaction term between the
antibody response and time (3 categories: t = 0–100, t = 100–150
and t.150 days) was included in the analysis. A range of
demographic, clinical and biological variables were assessed as
potential confounders of associations between antibodies and
malaria outcomes. Only host age and location of residence were
identified as being significantly associated with antibodies and
malaria outcomes [25,33]. Of note, parasitemia status at
enrolment and red blood cell polymorphisms were not associated
with malaria outcomes [33,34]. Therefore, multivariate analysis
was used to calculate adjusted hazard ratios using covariates of age
and location. Age was used as binary variable (,9 years, $9
years), as previous studies indicated that this stratification was the
most informative approach for assessing the effect of age [33].
Additional age groupings with narrower age ranges were explored
in the multivariate analysis; however, results using these groupings
in the analysis were not different to using age as a dichotomous
variable. Adjusting for host gender did not influence protective
associations. Some previous studies have stratified analyses based
on the presence or absence of parasitemia at baseline [35] because
it was found to influence antibody associations. However, in our
study, parasitemia at enrolment was not significantly associated
with malaria outcomes and including parasitemia status in the
analysis did not affect the multivariate regression models. There
was no significant difference in PfRh4 antibodies according to
gender. Furthermore, adjustments for gender in multivariate
models did not significantly alter model outputs; therefore, gender
was not included in the final model. Recombinant protein
constructs PfRh4.1, PfRh4.2, and PfRh4.4 were GST-fusion
proteins; reactivity to GST was very low, and was not associated
with risk of malaria, and deducting GST reactivity from the
reactivity to Rh4-GST fusion proteins did not affect analysis
outcomes. Reporting of study outcomes followed the MIOS
guidelines for malaria immuno-epidemiology observational studies
[22].
Immunofluorescence Microscopy (IFAs) and Western
Blots for PfRh4 Expression
Using blood samples collected at enrolment, erythrocytes were
separated from PBMCs by density centrifugation over a Ficoll-
Paque gradient (Ficoll-Paque Plus, Amersham, [36]. Parasites
were cultured for 36 hours until mainly segmented schizonts were
prevalent, washed twice in PBS, thin smears made, air dried then
fixed in methanol (220uC) for 2 minutes. Slides were treated for
10 minutes with 0.1% Triton X100 prior to blocking (30 minutes,
3% BSA), and then sequentially incubated with monoclonal anti-
PfRh4 (1:50) and polyclonal rabbit antibodies to P. falciparum
rhoptry neck protein PfRON4 (1:1000), anti-mouse-Alexa 594
(1:500) and anti-rabbit-Alexa 488 (1:750). A DAPI containing
mounting medium was added (VectaShield, Vector Labs). An
isolate was considered positive for PfRh4 expression only if at least
3 DAPI-positive schizonts stained positive with anti-PfRh4. For
western blots, protein extracts of P. falciparum schizonts were
obtained by Saponin lysis of a synchronized parasite culture [7].
Schizont pellets were boiled in reducing sample buffer. SDS
PAGE and Western Blot were performed using established
procedures. Monoclonal anti-PfRh4 antibody was used 1/500,
rabbit anti-Hsp70 1/500, anti-mouse-HRP conjugate 1/1000 and
anti-rabbit-HRP conjugate 1/25000, all in 1% casein. The
specificity of the PfRh4 MAb has been previously established by
demonstrating that it labels a protein of expected size in parasites
that are known to express pfrh4 gene, and does not label a similar
protein in parasites in which the pfrh4 gene has been disrupted
[32]. Isolates used included 3D7, HB3, W2mefDPfRh4 [6], HCS3
[37], XIE, Pf2004, Pf2006 [38].
Affinity-purification of Human Antibodies
Serum samples from adults and children in the study population
were screened for antibodies to PfRh4.2 and PfRh4.9 by ELISA
and a pool was made of ELISA-positive samples. Recombinant
antigen (PfRh4.2 or PfRh4.9) was coupled to CNBR activated
Sepharose (GE Healthcare). Pooled serum was filtered to remove
lipids/debris before incubating with the antigen-coupled resin
overnight (4uC). Bound antibodies were eluted in 106 1 ml steps
using 0.1 M Glycine pH 2.4, and pH adjusted with 30 ml Tris
pH 8.8 (3 M) and 20 ml NaCl (5 M). Eluates were pooled, dialysed
against PBS, filter-sterilized, and concentrated using Ultracel
columns (Millipore, MWCO 50 kDa). Concentration was deter-
mined by densitometry using known concentrations of human
IgG. After affinity purification, samples were tested for IgG
reactivity to a panel of recombinant merozoite proteins to validate
the procedure. This demonstrated that the PfRh4-affinity-purified
antibody fraction was enriched for PfRh4.9 reactivity, or PfRh4.2
reactivity, and the eluates from the column showed a marked
depletion of reactivity (data not shown). There was no depletion of
antibodies to other merozoite proteins.
Growth Inhibition Assays
Antibodies were tested for in vitro inhibition of growth over two
cycles of replication, as described previously [39,40], using the
3D7 parasite isolate. Neuraminidase-treated erythrocytes were
used in some assays [7]. All samples were tested in duplicate and
results were expressed as a percent growth in a PBS control.
Sequence Analysis of PfRh4
Regions encoding PfRh4.2 and PfRh4.9 were amplified and
sequenced (accession numbers HE610476–610500) using P.
falciparum genomic DNA extracted from infected blood samples
from children in the cohort or samples from other children and
adults in the same township as described [30,41,42]. To sequence
PfRh4.2, oligonucleotide primers PfRh4-A3-fwd 59 caaa-
taaaaaatgtcagtgatgtattcacac 39 and PfRh4-A3-rev 59 ga-
catttgtcttgtctcctatggtg 39 were used to amplify a 525 bp fragment
coding for PfRh4.2, as described in [30]. PfRh4.9 was amplified
using a hemi-nested PCR strategy [42]. In the primary PCR
reaction, two overlapping fragments were amplified (nucleotides
150–1423 and 730–2010 relative to the 3D7 reference sequence,
AF432854) using primers: Rh4-F1 (59aaaacacaccatacgaacaa 39)/
Rh4-R2 (59 tggataaacatatatcatcggta 39) and Rh4-F2 (59 acacaaa-
caagtttgaacataa 39)/Rh4_R3 (59 ttgttgaatagttttgtgtgtaaa 39). In the
secondary PCR reaction, three fragments were amplified (nucle-
otides 150–826, 730–1423 and 1340–2010) from the correspond-
ing primary PCR product using primers Rh4_F1/Rh4_R1 (59
tgttaaatgacaatcggaat 39), Rh4-F2/Rh4-R2 and Rh4F3 (59 tctcattc-
gataaaaataaatca 39). High quality PCR products were purified and
sequenced directly. Only polymorphisms found in two indepen-
dent PCR products were scored. If there was a discrepancy
between the two PCR products, a third PCR product was
sequenced to confirm the correct sequence. Using BLAST,
Malaria Immunity Targets PfRh4
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PhRh4.2 and PfRh4.9 sequences from further isolates were
identified in the Broad and Sanger Institutes’ database including
Pf_Senegal (Senegal), RO33 and Ghana (Ghana), RAJ116 and
ICH-CR14 (India), HB3 (Honduras), IT and 7G8 (Brazil), D10
(PNG), 3D7 (unknown origin) and Dd2 (SE Asia).
Results
Antibodies to PfRh4.2 and PfRh4.9 are Associated with
Age and Concurrent Parasitemia
We measured antibodies in all cohort samples to various regions
of PfRh4 expressed as recombinant proteins (Figure 1a). PfRh4.9,
expressed and purified as a his-tagged protein, was selected
because it contains the erythrocyte-binding region [32]. PfRh4.2
(GST-tagged) is located within the C-terminal region [6], and is
known to be recognised by human antibodies [7]. Two additional
proteins were expressed as GST-fusion proteins and evaluated;
these were PfRh4.4 and PfRh4.1. The prevalence of IgG against
PfRh4.2 and PfRh4.9 was high (94–96%) in the cohort (Table 1),
whereas there was no reactivity among samples from unexposed
Australian residents. The prevalence antibodies to PfRh4.2 and
PfRh4.9 was significantly higher in older children (p,0.01 and
p,0.001, respectively), and among children who were parasitemic
at time of sample collection (p = 0.042 and p,0.001 for PfRh4.2
and PfRh4.9, respectively), consistent with the specific acquisition
of antibodies from P. falciparum exposure. Antibodies levels also
tended to be higher among older children and those who had
active parasitemia (Figure 1b). There was a significant correlation
between antibodies against PfRh4.2 and PfRh4.9 (p,0.001;
Table 2), and antibodies to PfRh4.2 and PfRh4.9 were signifi-
cantly correlated with antibodies to other merozoite antigens, such
as EBA175 (p,0.001), suggesting that antibodies to PfRh4 are co-
acquired with other responses to merozoite antigens. Prior studies
have shown that antibodies generated in rabbits against recom-
binant PfRh4.2 and PfRh4.9 reacted specifically with native
PfRh4 [6,32], indicating that epitopes expressed by native proteins
are represented on the recombinant proteins we used in ELISAs.
In contrast, antibodies to the two other constructs, PfRh4.1 and
PfRh4.4, were generally low and antibodies were not significantly
associated with age or parasitemia status. This suggests that these
regions may not be naturally immunogenic, or contain no or few
antibody epitopes. Alternatively, the recombinant proteins may
not be appropriately folded to present epitopes; however, in the
absence of knowledge of the structure of PfRh4 this is difficult to
assess.
IgG Subclass Responses are Predominantly IgG1 and
IgG3
The nature of IgG subclasses can influence function [43], and
we found that IgG1 and IgG3, known as cytophilic subclasses,
formed the predominant responses (Table 1). Most children were
seropositive for PfRh4.2 specific IgG3 (93.3%), whereas seropos-
itivity for PfRh4.2 specific IgG1, IgG2 and IgG4 was much lower
(14.6%, 8.3%, and 2.4%, respectively). IgG3 to PfRh4.2 was
significantly higher among older children (p = 0.01–0.06) and
children with active parasitemia (p,0.01). IgG1 was the most
prevalent response against PfRh4.9 (74.3%) and was significantly
higher in parasitemic children (p,0.001), but was not associated
with age. The prevalence of PfRh4.9 specific IgG3 was 36.4%,
and was strongly associated with age (p,0.0001) and parasitemic
status (p,0.0001). There was no PfRh4.9 specific IgG2 and very
little IgG4 detected.
Antibodies to PfRh4 are Associated with a Reduced Risk
of Clinical Malaria and High-density Parasitemia
The design and longitudinal nature of the cohort study,
incorporating anti-malarial treatment at enrolment and active
follow-up with the application of sensitive molecular methods to
detect P. falciparum infections, enabled us to investigate relation-
ships between PfRh4 specific antibodies and re-infection, parasit-
emia of different densities and symptomatic malaria. A range of
factors were assessed for potential confounding of antibody
associations with malaria outcomes; of these, only host age and
residential location were identified as possible confounders
[33,34]. Total IgG, IgG1 and IgG3 against PfRh4.2 were all
significantly associated with protection from clinical malaria
(defined as parasitemia .5000 parasites/ml plus fever) when
comparing high and low antibody responders (HR 0.23,
p,0.0001; 0.36, p = 0.001 and 0.4, p= 0.003, respectively,
Table 3). Importantly, these associations remained significant
after adjustment for age and location of residence (adjusted HR
[aHR] 0.29, p = 0.001; 0.39, p = 0.004 and 0.51, p = 0.04,
respectively). The association between antibodies to PfRh4 and
age was modest, and adjusting for age, on its own, in survival
analyses did not significantly alter the hazard ratios (using age as a
dichotomous variable of ,9 and .9 years, or using multiple age
categories). Some previous studies have reported hazard ratios
stratified for parasitemia status at baseline because of an
interaction between antibodies, parasitemia and malaria risk.
Although antibodies were higher among those with current
parasitemia in this study, parasitemia at baseline was not
significantly associated with risk of malaria. Therefore, parasitemia
was not included as a confounding variable in our final analyses,
and survival analyses were not stratified by baseline parasitemia
status; adjusting for parasitemia at enrolment did not affect hazard
ratios. High levels of IgG and IgG3 against PfRh4.2 were also
significantly associated with a reduced risk of high-density
parasitemia (defined as .5000 parasites/ul; aHR: 0.51,
p = 0.028, and aHR: 0.52, p = 0.027, respectively; Supporting
data, Table S1).
High PfRh4.9-specific IgG3 was strongly associated with a
reduced risk of clinical malaria (HR: 0.14, p,0.0001; aHR: 0.18,
p = 0.002); this was the strongest association with protection seen
in this study. PfRh4.9 specific IgG3 was also predictive of
protection against high-density parasitemia (Table S1). Impor-
tantly, the strength and significance of the association remained
high after adjusting for age and residential location, and were not
affected by adjusting for parasitemia at enrolment. In contrast,
IgG1 was not significantly associated with protection. Antibodies
to PfRh4.1 and PfRh4.4 were low and not associated with
protection (data not shown). Due to the low prevalence of IgG2
and IgG4 to PfRh4, associations with protection were not
examined. None of the examined antibody levels was associated
with protection from re-infection per se.
The protective association for IgG3 to the PfRh4.9 recombinant
protein (which contains the erythrocyte-binding region) was
stronger than responses or the PfRh4.2 recombinant protein. To
explore this further, we included IgG3 responses to PfRh4.9 and
PfRh4.2 in multivariate analysis using the Cox proportional
hazards model. The association between IgG3 to PfRh4.9 and
reduced risk of malaria was unchanged and strongly associated
with protection, whereas the association between IgG3 to PfRh4.2
and protection was weaker and non-significant. This may suggests
that IgG3 to PfRh4.9 is the more important response in
contributing to protection from malaria in this cohort. Because
of a significant correlation between responses, interaction terms
Malaria Immunity Targets PfRh4
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Table 1. Prevalence and levels of antibodies to PfRh4 antigens.
All Age
2 Enrolment P. falciparum parasitemic status3
#9.0 yrs .9.0 yrs P4 PCR2 PCR+ P4
n=206 n=91 n=115 n=67 n=139
PfRh4.2
IgG
Seropositive1 195 82 113 0.01 60 135 0.042
% 94.7 90.1 98.2 90 97
Median OD 0.24 0.16 0.26 0.01 0.12 0.28 0.0001
[IQR] [0.08–0.64] [0.1–0.54] [0.12–0.7] [0.04–0.38] [0.12–0.71]
PfRh4.9 n=203
IgG
Seropositive1 195 82 113 0.001 58 137 ,0.0001
% 96.1 91.1 100 87.7 100
Median OD 1.23 1.15 1.25 0.6 0.81 1.35 ,0.0001
[IQR] [0.74–1.51] [0.54–1.58] [0.87–1.44] [0.32–1.25] [0.95–1.55]
PfRh4.4
IgG
Seropositive1 31 13 18 0.785 8 23 0.386
% 15.1 14.3 15.7 12.0 16.6 0.386
Median OD 0.12 0.12 0.12 0.571 0.12 0.12 0.995
[IQR] [0.08–0.19] [0.08–0.19] [0.08–0.2] [0.07–0.2] [0.08–0.19] 0.995
PfRh4.1
IgG
Seropositive1 78 34 44 0.895 24 54 0.675
% 37.9 37.4 38.3 35.8 38.9
Median OD 0.15 0.15 0.15 0.544 0.15 0.15 0.732




Seropositive1 30 10 20 0.2 5 25 0.045
% 14.6% 11.0% 17.4% 7.5% 18.0%
Median OD 0.06 0.04 0.06 0.36 0.04 0.06 0.056
[IQR] [0.01–0.12] [0.01–0.11] [0.01–0.13] [0–0.09] [0.02–0.13]
IgG2
Seropositive1 17 10 7 0.2 3 14 0.172
% 8.3% 11% 6.1% 4.5% 10.1%
Median OD 0.01 0 0.01 0.32 0 0 0.169
[IQR] [0–0.01] [0–0.01] [0–0.02] [0–0.11] [0–0.02]
IgG3
Seropositive1 182 77 105 0.06 50 132 0.003
% 93.3% 89.5% 96.3% 84.8% 97.1%
Median OD 0.19 0.13 0.25 0.01 0.1 0.25 ,0.0001
[IQR] [0.06–0.63] [0.04–0.44] [0.07–0.74] [0.02–0.25] [0.07–0.84] ,0.0001
IgG4
Seropositive1 5 2 3 1.0 2 3 0.661
% 2.4% 2.2% 2.6% 3.0% 2.16%
Median OD 0 0 0 0.15 0 0 0.138
[IQR] [0–0.01] [0–0.02] [0–0.01] [0–0.01] [0–0.02]
Malaria Immunity Targets PfRh4
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Table 1. Cont.
All Age
2 Enrolment P. falciparum parasitemic status3
#9.0 yrs .9.0 yrs P4 PCR2 PCR+ P4




Seropositive1 153 63 90 0.14 36 117 ,0.0001
% 74.3% 69.2% 78.3% 53.7% 84.2%
Median OD 0.41 0.39 0.44 0.25 0.21 0.54 ,0.0001
[IQR] [0.14–0.78] [0.10–0.86] [0.20–0.73] [0.04–0.48] [0.23–0.84]
IgG2
Seropositive1 0 0 0 – 0 0 –
% 0% 0% 0% 0% 0%
Median OD 0 0 0 0.22 0 0 0.111
[IQR] [0–0.02] [0–0.02] [0–0.02] [0–0.01] [0–0.02]
IgG3
Seropositive1 75 17 58 ,0.0001 12 63 ,0.0001
% 36.4% 18.7% 50.4% 17.9% 45.3%
Median OD 0.07 0.03 0.13 ,0.0001 0.03 0.11 ,0.0001
[IQR] [0.02–0.2] [0.01–0.86] [0.05–0.27] [0.01–0.07] [0.03–0.24]
IgG4
Seropositive1 15 5 10 0.38 4 11 0.778
% 7.3% 5.5% 8.7% 6.0% 7.9%
Median OD 0 0 0 0.3 0 0 0.130
[IQR] [0–0.02] [0–0.02] [0–0.03] [0–0.01] [0–0.03]
Notes:
1Seropositive (number of seropositive individuals) and percentage (%) of seropositive individuals were defined by IgG reactivity that was higher than the mean plus
three standard deviations of control sera (unexposed donors) measured by ELISA. Median optical densities (OD) are displayed; [IQR] - interquartile range.
2Age: #9.0 yrs indicates individuals younger than 9 years of age; .9.0 yrs indicates individuals older than 9 years of age.
3Parasitemic status: PCR-, indicates P. falciparum was not detected by PCR; PCR+, indicates P. falciparum was detected by PCR.
4P values were calculated using the chi-squared test or Fisher’s exact test for comparisons of seroprevalence, or using the Kruskal-Wallis test for comparisons of antibody
level.
doi:10.1371/journal.pone.0045253.t001
Table 2. Correlation between IgG and IgG subclass responses to PfRh4 proteins.
PfRh4.2 PfRh4.9 PfRh4.4




IgG3 0.81* 0.42* 20.01
IgG4 0.17 0.15 20.13 0.2
PfRh4.9 IgG 0.44* 0.24 20.002 0.42* 0.12
IgG1 0.43* 0.22 0.012 0.4* 0.09 0.94*
IgG2 0.16 0.09 0.33* 0.07 20.09 0.28* 0.24
IgG3 0.54* 0.33* 0.08 0.52* 0.08 0.36* 0.36* 0.2
IgG4 0.11 0.09 0.1 0.02 0.12 0.21 0.2 0.32* 0.19
PfRh4.4 IgG 0.34* 0.24 0.1 0.27 0.13 0.07 0.08 20.02 0.16 0.02
PfRh4.1 IgG 0.45* 0.32* 0.03 0.35* 0.05 0.34* 0.36* 20.02 0.2 20.03 0.53*
Notes: Correlation coefficients are Spearman’s rho.*: p,0.0001. Bold: p,0.05. Others: not significant. IgG: total IgG. Antibodies measured by ELISA.
doi:10.1371/journal.pone.0045253.t002
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could not be explored to investigate any potential synergistic or
additive effects of different antibody responses.
Human Antibodies Against PfRh4 Inhibit Invasion of
Erythrocytes
To assess the functional activity of PfRh4 antibodies, we affinity
purified human anti-PfRh4.9 and PfRh4.2 antibodies and tested
them for P. falciparum growth-inhibitory activity in vitro. Neur-
aminidase treatment of erythrocytes was used to inhibit the use of
alternate invasion pathways and force merozoites to use PfRh4
during invasion [6,12]. Purified PfRh4.9 antibodies inhibited
invasion into untreated (Figure 2a) and neuraminidase-treated
erythrocytes (Figure 2b) in a concentration-dependent manner.
Inhibition of invasion was much stronger in neuraminidase treated
erythrocytes, with an IC50 of 23 mg/ml (invasion into untreated
cells was inhibited by 40% at 100 mg/ml). The greater inhibition
of invasion into neuraminidase-treated cells reflects the reliance on
PfRh4 by merozoites during invasion, and points to the specificity
of the affinity-purified PfRh4 antibodies. To determine whether
PfRh4.9 antibodies were present in protected children at
sufficiently high levels to inhibit invasion, we directly compared
the reactivity of antibodies among high responders (defined as the
upper tertile) from the cohort with the reactivity of the affinity-
purified invasion-inhibitory antibodies using ELISA (Figure 2c);
results suggested that children did have sufficiently high enough
concentrations for functional activity. IgG reactivity for the
affinity-purified PfRh4.9 was 2–4 times higher than that seen for
high-responder children; since the purified IgG inhibited growth
by 50% by a 1/54 dilution (23.3 mg/ml), and by 75% at a 1/42
dilution (30.1 mg/ml), the children’s samples would be expected to
inhibit by similar amounts at a 1/10–1/27 dilution. In contrast,
human antibodies against PfRh4.2 (tested at a maximum
concentration of 300 mg/ml) did not substantially inhibit invasion
into either untreated or neuraminidase treated erythrocytes
(Figure 2d).
PfRh4 Expression in Isolates from Infected Children
To determine the extent of PfRh4 expression and its potential as
an immune target, we assessed PfRh4 protein expression among
isolates infecting individuals in the cohort by immunofluorescence
microscopy. To maintain the original phenotype, P.falciparum
isolates were only cultured in vitro until schizont-stages were
prevalent, but were not cultured through new cycles of invasion
and replication. Laboratory adapted isolates 3D7 and HB3 were
used as positive controls, with a PfRh4 knockout mutant as a
negative control (the monoclonal antibody to PfRh4 did not label
the PfRh4-knockout parasite line by IFA or western blot. We also
stained for RON4, another rhoptry protein, to verify the location
of PfRh4 staining. We found that 15 out of 22 isolates from
infected children showed expression of PfRh4 proteins and were
classified as positive (Table 4; Figure 3a). This suggests that PfRh4
is an important invasion ligand in this population. Previous reports
of laboratory-adapted isolates show that 73% express PfRh4
(Supporting data, Table S2). Testing four recently adapted isolates
[38] of different geographic origins by Western Blot, we found that
isolates XIE010 (origin - PNG) and Pf2004 (Ghana) showed PfRh4
expression, whereas Pf2006 (Ghana) and HCS3 (Thailand) were
PfRh4-negative (Figure 3b).
Limited Sequence Polymorphism in PfRh4
To further understand the importance of PfRh4 as an immune
target and its potential as a vaccine candidate, we sequenced the
regions coding for PfRh4.2 and PfRh4.9 in clinical isolates
obtained in the population (Table 5). In the region of PfRh4.2, we
found no SNPs among 13 isolates from the cohort and 16 isolates
from diverse geographic origins. For PfRh4.9, we determined
sequences from 12 isolates in the cohort; there were four SNPs
resulting in one synonymous and 3 non-synonymous changes. In
11 sequences from public databases (plus isolate HCS3) there were
5 additional polymorphic sites, (1 synonymous, 4 non-synony-
mous). The 3 non-synonymous changes in the cohort sequences
were also found in sequences from the databases. Furthermore, 11
of the sequences were identical to the reference strain 3D7, and 10
sequences differed at only 1 or 2 sites. The average nucleotide
diversity (p) was 0.00095, and there was no departure from
neutrality was detected by Tajima’s D value for population data
(n = 12) or the Hudson-Kreitman-Aguade ratio for all data (n = 23)
[44]. Thus, there is no evidence of significant selective pressure in
the N-terminal region of PfRh4.
Discussion
These findings represent a significant advance towards identi-
fying targets of human immunity to malaria. Our broad evaluation
of PfRh4 combining prospective studies of associations between
antibodies and protective immunity, the functional activity of
human antibodies, and PfRh4 expression by P. falciparum in the
population provide important evidence, for the first time,
suggesting that PfRh4 is a target of human immunity.
IgG1 and IgG3 were the predominant subclasses for antibodies
to PfRh4, with very little IgG2 or IgG4, as observed for other
Table 3. Associations between antibodies and risk of clinical malaria.
Antigen uHR MvL [95% CI] p uHR HvL [95% CI] p aHR MvL [95% CI] p aHR HvL [95% CI] p
PfRh4.2 IgG 0.56[0.33–0.95] 0.03 0.23[0.12–0.47] ,0.0001 0.66[0.38–1.14] 0.138 0.29[0.14–0.58] 0.001
IgG1 0.58[0.33–1.0] 0.048 0.36[0.2–0.67] 0.001 0.64[0.36–1.12] 0.118 0.39[0.21–0.74] 0.004
IgG3 0.53[0.3–0.92] 0.023 0.4[0.22–0.73] 0.003 0.64[0.36–1.13] 0.122 0.52[0.28–0.98] 0.043
PfRh4.9 IgG 0.62[0.26–1.5] 0.293 0.68[0.29–1.58] 0.368 0.71[0.3–1.73] 0.454 0.73[0.31–1.71] 0.462
IgG1 0.41[0.16–1.06] 0.065 0.73[0.33–1.65] 0.451m 0.49[1.88–1.29] 0.148 0.83[0.37–1.88] 0.662
IgG3 0.11[0.03–0.36] ,0.0001 0.14[0.05–0.41] ,0.0001 0.12[0.04–0.4] 0.001 0.18[0.06–0.54] 0.002
Notes: Study participants (n = 206) were stratified into 3 equal groups according to low, medium or high levels of antigen-specific antibodies. Hazard ratios were
calculated comparing high versus low levels of antibodies (HvL) and medium versus low levels (MvL) of antibodies for the risk of symptomatic malaria over 6 months of
follow-up; analysis was based on first episode only. Unadjusted hazard ratios (uHR), adjusted (age-adjusted and location-adjusted) hazard ratios hazard ratios (aHR) and
95% confidence intervals [95% CI] were calculated. During the follow-up period, 80 children experienced at least one episode of clinical malaria, and 196 were re-
infected (as detected by PCR).
doi:10.1371/journal.pone.0045253.t003
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merozoite antigens [25,30,31,45]. High levels of IgG3 to PfRh4.9,
containing the erythrocyte-binding region, were very strongly
associated with reduced malaria risk; this is the strongest
association with protection against malaria that we have observed
in this cohort [25,30,31]. Importantly, this protective association
remained strong and significant after adjusting for potential
confounding factors of age, residential location, and parasitemia
status at enrolment. High levels of IgG3 to PfRh4.2 were also
strongly associated with protection against clinical malaria and
high-density parasitemia, but this association was not as strong as
that seen for IgG3 to PfRh4.9. Interestingly, IgG1 to PfRh4.9 was
not significantly associated with protective immunity, suggesting
that IgG3 might be functionally more important. Although a
detailed knowledge of the functions of IgG subclasses in humans is
lacking, prior studies report important differences in the function
of IgG1 and IgG3 in other systems (eg. [46]), and known structural
differences between IgG1 and IgG3 may influence specificity and
function. Animal studies indicate that different IgG subclasses have
different immunologic activities and roles, and lead to different
outcomes [43]. Further studies are needed to understand the
functional differences between IgG1 and IgG3 to PfRh4 and other
merozoite antigens. The association between high levels of
antibodies and protection from high-density parasitemia, but not
re-infection per se, is consistent with PfRh4 antibodies acting by
inhibition of erythrocyte invasion and parasite replication, which
we observed in vitro. Human immunity to malaria is almost
certainly mediated by responses to multiple target antigens, but
few of these target antigens have been identified or studied in
detail. Data presented here provide important evidence that
antibodies to PfRh4 contribute to the protective immune response
in humans. We have previously reported that antibodies to the
EBAs and PfRh2 [25,30,31] are strongly associated with
protection; collectively, these studies identify the EBA and PfRh
invasion ligand families as important targets of immune responses
in humans that appear to contribute to protection against malaria.
Given that P. falciparum can vary the use and expression of EBA
and PfRh4 invasion ligands as a possible means of immune evasion
[7], it is likely that functional antibodies to multiple invasion
ligands would be needed to provide effective immunity.
Demonstrating the functional significance of PfRh4 antibodies,
affinity-purified human antibodies against the PfRh4.9 protein,
which contains the erythrocyte-binding region, were potent
inhibitors of SA-independent invasion, which requires the PfRh4
ligand. To our knowledge, this is the first report of human IgG to
PfRh4 being invasion-inhibitory and one of the strongest lines of
evidence that human antibodies specific to an invasion ligand may
play an important role in immunity. Comparisons between
antibody levels to PfRh4.9 in samples from children and the
concentration of affinity-purified antibodies for invasion inhibition
suggested that protected children have sufficiently high antibody
levels to have inhibitory activity against P. falciparum. These data
complement our findings of an association between antibodies to
Figure 2. Inhibition of erythrocyte invasion by affinity-purified
human PfRh4 antibodies. (a) Concentrationdependent inhibition of
invasion by affinity-purified human antibodies to recombinant PfRh4.9.
Increasing concentration of PfRh4.9 antibody (black bars) resulted in
increased invasion inhibition into untreated erythrocytes, whereas
varying concentrations of human non-immune IgG had no effect (white
bars). (b) Concentration-dependent invasion inhibition by PfRh4.9
antibodies into neuraminidase treated erythrocytes. Results for (a)
and (b) show means from 2 independent experiments, each run in
duplicate, and are expressed as % growth compared to PBS control.
Error bars represent the SEM between all 4 values. Anti-Rh4.9 rabbit
antibodies, a known inhibitor of invasion, was used as a control (grey
bars). (c) ELISA results plotted as OD at 405 nm (y-axis) to compare
concentrations of affinity purified PfRh4.9 antibodies and high
responders (samples A–F) from the Mugil cohort. Different dilutions
as indicated on the x-axis have been tested on recombinant PfRh4.9. (d)
Invasion inhibition mediated by anti-PfRh4.2 antibodies (at 300 mg/ml)
in relation to invasion inhibition mediated by non-specific human IgG
(250 mg/ml). Results represent the mean from two independent
experiments, each sample tested in duplicate. Error bars represent
the SEM; ut: untreated erythrocytes, N: Neuraminidase treated
erythrocytes.
doi:10.1371/journal.pone.0045253.g002
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PfRh4 and protection from malaria, providing evidence that
PfRh4 is a target of protective antibodies. In contrast, human
PfRh4.2 antibodies did not inhibit invasion of erythrocytes.
Hence, the functional relevance of PfRh4.2 antibodies is unclear,
and they may have a different mode of action, such as interactions
with Fc-receptors on immune cells or with complement. Alterna-
tively, antibodies to PfRh4.2 may be a marker of immunity, or of
responses to PfRh4 more broadly, rather than directly contribut-
ing to immunity. Presently, the acquisition of human growth-
inhibitory antibodies to merozoite antigens has only been
demonstrated for AMA1 and MSP1-19 [47,48], and with some
evidence supporting EBA175 as an additional target [7]. Studies
have not previously related the antibody levels required for
functional activity to levels present in protected individuals as we
have done. Prior studies suggest that MP1-19 is not a major target
of inhibitory antibodies in this population [49].
Most isolates infecting children demonstrated PfRh4 protein
expression, consistent with our data suggesting PfRh4 may be an
important target of acquired immunity. There are no prior reports
of PfRh4 protein expression in clinical isolates, but two studies of
African children found that pfrh4 gene expression was detected in a
minority of isolates [19,20]. Differences between these studies and
ours may represent population-specific differences, or differences
in the sensitivity of the methods used. Consistent with our studies
on clinical isolates, most culture adapted isolates (from diverse
geographic origins) show expression of PfRh4 protein. Further
studies are needed to assess a larger number of isolates in different
populations and relationship between PfRh4 expression and
acquired antibodies. Sequence analysis identified little polymor-
phism in the PfRh4 erythrocyte-binding region and no polymor-
phisms in the PfRh4.2 region. In contrast, PfRh2 has a highly
polymorphic stretch in the N-terminal region [30] that encodes the
erythrocyte-binding domain [50,51]. It is possible the variable
expression of PfRh4 is used a means of immune evasion [7], rather
than immune evasion via the evolution of polymorphisms. The
limited polymorphism in PfRh4 may make it attractive as a
vaccine candidate, especially when partnered with other antigens,
such as EBA175, to block the use of alternate invasion pathways
[7,52]. PfRh5 also has limited polymorphisms [53], and a recent
report suggested that there was minimal acquisition of IgG to
recombinant PfRh5 in a population of malaria-exposed Kenyans
[54]. One study reported that expression of the pfrh5 gene was
variable among P. falciparum isolates in The Gambia [20], as seen
for other pfrh genes, whereas other data suggests PfRh5 protein is
expressed by all laboratory-adapted isolates [53,54]. Our prelim-
inary studies suggest that the prevalence of antibodies to
recombinant PfRh5 is high in our PNG study population (J.
Richards, J. Beeson, unpublished observations). Further studies to
understand the expression of PfRh ligands and the acquisition of
antibodies to them will be valuable for understanding the
importance of PfRh proteins as targets of immunity and their
potential for vaccine development.
Table 4. Expression of PfRh4 in clinical isolates from PNG.
Isolate Number of schizonts counted Proportion PfRh4 positive (%) PfRh4 expression
A 32 31.3 +
B 5 20 unclear
C 23 56.5 +
D 39 46.1 +
E 15 46.7 +
F 12 2 2
G 21 57 +
H 16 81.3 +
I 16 6.25 unclear
J 15 66.7 +
K 31 87.7 +
L 10 90 +
M 10 90 +
N 37 2 2
O 15 2 2
P 20 30 +
Q 24 41.7 +
R 52 34.6 +
S 7 2 2
T 28 2 2
U 54 77.8 +
V 61 50.8 +
3D7 117 40.1 +
Notes: Results from immunofluorescence assays using blood smears of P. falciparum isolates from infected children. Isolates A–V were stained with DAPI and anti-PfRh4
antibody in order to investigate the rate of PfRh4 expression in clinical isolates. % Rh4 positive: proportion of DAPI-positive schizonts that were also PfRh4-positive. An
arbitrary cut-off for positivity was set at 3 DAPI-positive schizonts that were also Rh4-positive. As a reference, schizonts of isolate 3D7 were stained with anti-PfRh4
antibody in 4 independent experiments to determine the average percentage of positive PfRh4 staining (mean 40.1%, range of 20.7%).
doi:10.1371/journal.pone.0045253.t004
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Understanding the targets of acquired human immunity is
valuable for several reasons. One of the important criteria for
objectively prioritizing antigens for vaccine development against
malaria, as with other infectious pathogens, is the demonstration
that immune responses to that antigen are associated with
protection from malaria [22,23]. As noted earlier, there is
presently a major deficiency in our knowledge of human immune
responses to the many potential blood-stage antigens of human
malaria. Furthermore, our level of understanding human immune
responses to complex pathogens is very limited. Knowledge of
immunity to infectious diseases is largely based on studies of much
simpler organisms (viruses and some bacteria) that have much
smaller genomes than complex organisms such as P. falciparum, and
have few target antigens. Often this knowledge also relies heavily
on principles established in small animal models that may not be
wholly representative of human disease and immune responses.
There is increasing interest in using serological assays as a low cost
tool for surveillance of malaria exposure in populations to guide
control efforts by identifying populations at risk, and evaluating
the impact of malaria control interventions on malarial immunity,
and this is arising as a major potential application of a detailed
knowledge of human immunity to malaria. Identifying key
antibody targets would advance these strategies and facilitate the
development of biomarkers to monitor immunity in populations.
In conclusion, our findings suggest PfRh4 is a target of human
antibodies that contribute to protective immunity, and PfRh4 may
warrant further consideration in malaria vaccine development.
The PfRh ligands are not present in rodent or simian malarias
and, therefore, responses to PfRh ligands cannot be easily studied
in animal models. This emphasizes the importance of human
studies to evaluate these antigens as targets of protective immunity
and aid the identification and prioritization of candidates for
vaccine development. Furthermore, the broad approach used here
to evaluate PfRh4 as an immune target could serve as a valuable
framework to assess and prioritize numerous other merozoite
antigens being identified in the post-genomic era as immune
targets and potential vaccine candidates.
Figure 3. Expression of PfRh4 in clinical isolates and culture-adapted strains. (a) A representative example of a schizont from a clinical P.
falciparum isolate with PfRh4 expression, as determined by immunofluorescence microscopy. Order of panels: phase, DAPI stain (labels nucleus), anti-
Ron4-Alexa 488, anti-Rh4-Alexa-597, overlay. (b) Western blots showing expression of PfRh4 by P. falciparum isolates recently adapted to in vitro
culture. Proteins were extracted from schizonts and the membrane was probed with anti-PfRh4 antibodies (upper panel) and anti-HSP70 antibodies
(lower panel) as a loading control. The positions of molecular weight standards are indicated on the left. Isolates tested were 3D7, XIE (from PNG),
Pf2004 (Ghana), Pf2006 (Ghana), HCS3 (Thailand) and a W2mef-PfRh4 knockout line (Rh4ko).
doi:10.1371/journal.pone.0045253.g003
Table 5. Polymorphisms within regions of PfRh4.
N bp SNPs h S NS
I PfRh4.2 13 525 0 1 0 0
PfRh4.9 12 1817 4 4 1 3
II PfRh4.2 16 525 0 1 0 0
PfRh4.9 11 1648–1817* 8 6 1 7
III PfRh4.2 29 525 0 1 0 0
PfRh4.9 23 1648–1817* 9 7 2 7
Notes: Sequence analysis of PfRh4.2 and PfRh4.9 in clinical isolates derived from
the Mugil population (I), global sequences of diverse geographic origins (II) and
the combined datasets (III). For global sequences, we sequenced isolate HCS3,
and obtained sequences for 3D7, Dd2, HB3, 7G8, FVO, CS2, D6, FCC2, IGH-CR14,
K1, Pf_Senegal, SL and VS/1, IT line and Ghana from the Broad Institute and
Sanger Institute public databases. N: number of isolates tested. bp: length of
fragment sequenced in bp (PfRh4.2: bp 3829–4353; PfRh4.9: bp 170–1987).
*: length of fragment varied between 1648bp and 1817 bp. SNPs: total number
of single nucleotide polymorphisms observed in all sequences. h: total number
of haplotypes observed. S: total number of synonymous mutations in all
sequences. NS: total number of non-synonymous mutations in all sequences.
doi:10.1371/journal.pone.0045253.t005
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Supporting Information
Table S1 Association between antibodies and risk of
high-density parasitemia. Study participants were stratified
into 3 equal groups according to low, medium or high levels of
antigen-specific antibodies. Hazard ratios were calculated com-
paring those with high versus low levels of antibodies (HvL) and
medium versus low levels (MvL) of antibodies for the risk of high-
density parasitemia (.5000 parasites/ml blood) over 6 months of
follow-up; analysis was based on first episode only. Unadjusted
hazard ratios (uHR), and adjusted (age-adjusted and location-
adjusted) hazard ratios hazard ratios (aHR) were calculated.
(DOCX)
Table S2 Expression of PfRh4 by laboratory-adapted
isolates. Note on isolates: *Isolates W2mef and Dd2 are thought
to be genetically identical; # isolates FCR3 and E8B (a clone of the
IT line) are thought to be genetically identical. References: Tham
WH, Schmidt CQ, Hauhart RE, Guariento M, Tetteh-Quarcoo
PB, et al. (2011). Plasmodium falciparum uses a key functional site
in complement receptor type-1 for invasion of human erythro-
cytes. Blood 118:1923–1933; Stubbs J, Simpson K, Triglia T,
Plouffe D, Tonkin C, et al. (2005), Molecular mechanism for
switching of P. falciparum invasion pathways into human
erythrocytes. Science 309:1384–1387; Gaur D, Furuya T, Mu J,
Jiang LB, SuXZ, et al. (2006) Upregulation of expression of the
reticulocyte homology gene 4 in the Plasmodium falciparum clone
Dd2 is associated wit a switch in the erythrocyte invasion pathway.
Molec Biochem Parasitol 145:205–215.
(DOCX)
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